Search
Cancer Clinical Trials in Sarasota, FL
A listing of 53 Cancer clinical trials in Sarasota, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 53
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Sarasota, Florida, currently has 53 active clinical trials seeking participants for Cancer research studies.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Irritability Associated with Autism (Children and Adolescents) Study
Recruiting
Become part of a clinical trial today and play a role in driving medical research forward, aiding in the discovery of groundbreaking therapies. Get rewarded for your time with monetary compensation and enjoy access to medical treatment at no charge.
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Recruiting
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.
The main question[s] it aims to answer are:
to evaluate the safety and tolerability of single agent and combination therapy
to determine the recommended dose for Phase 2 of single agent and combination therapy
to determine the pharmacokinetics of TNG348 as a single agent and in c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Recruiting
This study will evaluate the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Solid Tumor, Breast Cancer
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Recruiting
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Sarasota Memorial Hospital, Sarasota, Florida
Conditions: Bladder Cancer
NOLA (NeuWave Observational Liver Ablation) Registry
Recruiting
This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.
Gender:
All
Ages:
22 years and above
Trial Updated:
04/23/2024
Locations: Sarasota Memorial Hospital, Sarasota, Florida
Conditions: Cancer of the Liver, Liver Cancer, Neoplasms, Liver
A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Recruiting
A Phase 2 study to evaluate the clinical activity, safety, and potentially predictive biomarker profile of ZN-c3 in subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Site 0181 - Sarasota Memorial Health Care System, Sarasota, Florida
Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
Recruiting
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Florida Cancer Specialists SAC, Sarasota, Florida +1 locations
Conditions: Advanced Breast Cancer
(VELA) Study of BLU-222 in Advanced Solid Tumors
Recruiting
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma, Advanced Solid Tumors, HR+ Breast Cancer
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Recruiting
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Sarasota Memorial Hospital, Sarasota, Florida
Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Florida Cancer Specialists - Sarasota, Sarasota, Florida
Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Recruiting
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Florida Cancer Specialists - Sarasota, Sarasota, Florida
Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Florida Cancer Specialists - Sarasota, Sarasota, Florida
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
1 - 12 of 53